FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Corporation (NASDAQ:BRKR) – Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Bruker in a note issued to investors on Tuesday, January 6th. Zacks Research analyst Team now expects that the medical research company will earn $1.89 per share for the year, down from their prior forecast of $1.90. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.65 EPS and FY2027 earnings at $2.44 EPS.

A number of other analysts also recently commented on BRKR. Wells Fargo & Company boosted their target price on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Rothschild & Co Redburn assumed coverage on Bruker in a research report on Thursday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Redburn Partners set a $60.00 price objective on Bruker in a research note on Thursday, November 20th. Wolfe Research upgraded Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Wednesday, December 10th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $52.29.

Bruker Price Performance

Shares of Bruker stock opened at $54.46 on Thursday. Bruker has a 52 week low of $28.53 and a 52 week high of $64.64. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. The stock has a market cap of $8.27 billion, a PE ratio of -340.38, a price-to-earnings-growth ratio of 6.80 and a beta of 1.17. The company’s 50-day moving average price is $46.14 and its two-hundred day moving average price is $39.74.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The company had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

Insiders Place Their Bets

In other Bruker news, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several large investors have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd bought a new position in Bruker during the second quarter valued at approximately $192,735,000. AQR Capital Management LLC increased its position in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Sculptor Capital LP raised its holdings in Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after buying an additional 476,363 shares in the last quarter. Brown Advisory Inc. raised its holdings in Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after buying an additional 336,026 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. lifted its position in shares of Bruker by 61.6% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after buying an additional 796,510 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker News Roundup

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Bruker said it acquired the remaining 60% of TOFWERK, taking full ownership to 100% and folding TOFWERK’s ultra-fast TOF mass‑spectrometry tech into Bruker’s applied markets push (air quality, exposomics, food/flavor, atmospheric chemistry). This is a strategic product/market expansion that can drive revenue diversification and higher-margin applied‑markets growth. Bruker Consolidates Ownership of TOFWERK
• Positive Sentiment: Bruker’s BEST division announced roughly $500 million in multi‑year supply agreements with two global radiology customers to supply advanced superconductors for MRI magnets — a material long‑lead, high‑value product that supports recurring revenue and visibility. That large contract flow is the primary near‑term catalyst cited by market reports. Bruker Announces $500 Million in Multi-Year Orders
• Positive Sentiment: TD Cowen raised its price target on BRKR to $53.00, signaling incremental analyst support for the stock’s outlook (note: analyst moves can boost sentiment even if PTs lag recent prices). TD Cowen Boosts Bruker Price Target
• Positive Sentiment: A recent Seeking Alpha piece argues BRKR may be attractively valued ahead of an earnings inflection, reinforcing a bullish narrative among value/growth investors. Bruker: Attractive Valuation Ahead Of An Earnings Inflection
• Neutral Sentiment: Bruker is scheduled to present at the J.P. Morgan Healthcare Conference — a visibility event that can catalyze investor interest but is informational rather than an operational development. Bruker Corporation to Present at the J.P. Morgan Healthcare Conference
• Negative Sentiment: Zacks Research trimmed Q4/FY EPS estimates marginally (Q4 to $0.65, FY2025 to $1.89 and FY2027 to $2.44), reflecting modest near‑term analyst downgrades that could limit upside if guidance/earnings miss. Zacks trims EPS estimates for Bruker

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.